MedTrace Logo

Interstitial Lung Disease and Obstructive Sleep Apnea

NCT05838183 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-02-10

No results posted yet for this study

Summary

Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease.

All patients undergo polysomnography (PSG) and drug-induced sleep endoscopy(DISE). The biological specimens was obtained for molecular biology or other tests.We detected ZNF331, Claudin1, Claudin2, Claudin3, Claudin4, and IL22 as biomarkers to differentiate the diagnostic efficiency of OSA in ILD, ILD+OSA, OSA, and Ctrl groups, respectively

Conditions

  • ILD OSA

Interventions

DIAGNOSTIC_TEST

The relationship between imaging and ROSE and NGS

The correlation between ROSE and NGS in imaging and bronchoscopy of ILD patients was observed

Sponsors & Collaborators

  • Dan Liu

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05838183 on ClinicalTrials.gov